Tobias Carling


Affiliation: Yale University
Country: USA


  1. request reprint
    Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol. 2005;17:7-12 pubmed
    ..Improved understanding of the molecular and clinical genetics associated with these lesions will likely enhance the diagnosis and treatment of patients with these diseases...
  2. Brown T, Murtha T, Rubinstein J, Korah R, Carling T. SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior. Cell Commun Signal. 2018;16:27 pubmed publisher
  3. Erinjeri N, Nicolson N, Deyholos C, Korah R, Carling T. Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular Thyroid Cancer. J Am Coll Surg. 2018;226:950-959.e5 pubmed publisher
    ..Next-generation sequencing tools can be used to identify druggable signaling targets for precision treatment of FTCs. ..
  4. Brown T, Nicolson N, Cheng J, Korah R, Carling T. Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics. J Vis Exp. 2018;: pubmed publisher
    ..We propose these assays to provide relatively simple, reliable, and easily interpretable metrics to measures these characteristics under various experimental conditions. ..
  5. Rubinstein J, Brown T, Goh G, Juhlin C, Stenman A, Korah R, et al. Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma. Surgery. 2016;159:296-301 pubmed publisher
    ..Further functional analysis of individual genes within these regions could provide mechanistic insight into specific drivers underlying pathogenesis and progression of ACC. ..
  6. Kunstman J, Juhlin C, Goh G, Brown T, Stenman A, Healy J, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet. 2015;24:2318-29 pubmed publisher
    ..This first comprehensive exome-wide analysis of the mutational landscape of ATC identifies novel genes potentially associated with ATC tumorigenesis, some of which may be targets for future therapeutic intervention. ..
  7. Rubinstein J, Brown T, Christison Lagay E, Zhang Y, Kunstman J, Juhlin C, et al. Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma. BMC Cancer. 2016;16:646 pubmed publisher
    ..These late events are enriched for predicted-deleterious variants, suggesting a mechanism of genomic instability in PTC tumorigenesis. ..
  8. Sasanakietkul T, Carling T. Primary hyperparathyroidism treated by transoral endoscopic parathyroidectomy vestibular approach (TOEPVA). Surg Endosc. 2017;31:4832-4833 pubmed publisher
    ..It is a more direct approach than other remote endoscopic parathyroidectomy techniques. TOEPVA is an excellent option for select patients with pHPT wishing to avoid a neck incision. ..
  9. Sasanakietkul T, Murtha T, Javid M, Korah R, Carling T. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. Mol Cell Endocrinol. 2018;469:23-37 pubmed publisher
    ..This review outlines the current understanding of epigenetic alterations observed in PDTC and ATC and explores the potential for exploiting this understanding in developing novel therapeutic strategies. ..


More Information


  1. Brown T, Nicolson N, Korah R, Carling T. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/?-Catenin Activating Event Driving Adrenocortical Malignancy. J Am Coll Surg. 2018;226:988-995 pubmed publisher
    ..These findings suggest that BCL9 overexpression may serve as an alternative driver of constitutive Wnt/?-Catenin activation in ACC and could represent a potential molecular and diagnostic marker of tumor malignancy. ..
  2. Stenman A, Juhlin C, Haglund F, Brown T, Clark V, Svahn F, et al. Absence of KMT2D/MLL2 mutations in abdominal paraganglioma. Clin Endocrinol (Oxf). 2016;84:632-4 pubmed publisher
  3. Brown T, Juhlin C, Healy J, Stenman A, Rubinstein J, Korah R, et al. DNA copy amplification and overexpression of SLC12A7 in adrenocortical carcinoma. Surgery. 2016;159:250-7 pubmed publisher
    ..05). SLC12A7 gene amplification and overexpression occurs frequently in ACCs and may represent a novel molecular event associated with ACC. ..
  4. Murtha T, Korah R, Carling T. Suppression of cytochrome P450 4B1: An early event in adrenocortical tumorigenesis. Surgery. 2017;161:257-263 pubmed publisher
    ..Sensitization of adrenocortical carcinoma cells engineered to overexpress CYP4B1 further supports this notion. ..
  5. Cheng J, Brown T, Murtha T, Stenman A, Juhlin C, Larsson C, et al. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis. BMC Cancer. 2017;17:164 pubmed publisher
  6. Murtha T, Brown T, Rubinstein J, Haglund F, Juhlin C, Larsson C, et al. Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma. Surgery. 2017;161:1667-1674 pubmed publisher
    ..05). Frequent upregulation in adrenocortical carcinomas and the reversal of chemoresistance in adrenocortical carcinoma cells via enforced silencing suggest a role for CYP2A6 in adrenocortical malignancy. ..
  7. Javid M, Sasanakietkul T, Nicolson N, Gibson C, Callender G, Korah R, et al. DNA Mismatch Repair Deficiency Promotes Genomic Instability in a Subset of Papillary Thyroid Cancers. World J Surg. 2018;42:358-366 pubmed publisher
    ..MMR deficiency, potentially promoted by FOXO1 suppression, may explain the etiology for PTC development in some patients. FTC and FTA retain MMR activity and are likely caused by a different tumorigenic pathway. ..